Discuss the last updates of FDA, EMA and ITC safety guidelines with industry experts at IQPC?s 4th Clinically Relevant Drug Transporters, 22-23 April in Berlin. Find out how the guidelines help to implement a rational investigation of transporters and accelerate drug development
Among the central conference topics of discussions are the following:
-How to take advantage of transporters to design a favourable PK profile of the selected compounds
-The clinical translational phase with in vitro inhibition results and its correlation to in vivo findings in patients
-Strategies to assess transporter mediated DDI to give a realistic prediction with best practice case studies
-The importance of transport polymorphism and ethnic differences to conduct more effective assays for compounds? development
All of these core questions will be discussed with experts from market-leading pharmaceutical companies on site. For more in-depth learnings, delegates can take part in an evening workshop on Monday, April 22, on the impact of tissue injury and disease on drug transporters, by Mr. Imad Hanna of the Novartis Research Center and Ms. Lauren Aleksunes of the Department of Pharmacology and Toxicology at Rutgers University.
For more information and relevant downloads, like interviews and white papers, go to
www.drug-transporters.com
You must be logged in to post a comment Login